Suppr超能文献

基于 MRI 的惰性眼眶淋巴瘤根治性放疗后长期随访:影像学缓解标准和体积回归动力学。

MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics.

机构信息

Department of Radiotherapy, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Department of Oral and Maxillofacial Surgery, University of Duisburg-Essen, Kliniken-Essen-Mitte, Essen, Germany.

出版信息

Sci Rep. 2023 Mar 23;13(1):4792. doi: 10.1038/s41598-023-31941-w.

Abstract

We systematically analyzed the kinetics of tumor regression, the impact of residual lesions on disease control and the applicability of the Lugano classification in follow-up MRI of orbital non-Hodgkin lymphomas that were irradiated with photons. We retrospectively analyzed a total of 154 pre- and post-irradiation MRI datasets of 36 patients with low-grade, Ann-Arbor stage I, orbital non-Hodgkin lymphomas. Patients with restricted conjunctival involvement were excluded. Lymphoma lesions were delineated and volumetrically analyzed on T1-weighted sequences. Tumor residues were present in 91.2% of all cases during the first six months after treatment. Volumetric partial response rates (> 50% volume reduction) were 75%, 69.2%, and 50% at 12-24 months, 36-48 months and > 48 months after the end of treatment. The corresponding complete response (CR) rates according to the Lugano classification were 20%, 23.1% and 50%. During a median clinical follow-up of 37 months no significant differences in progression free survival (PFS) rates were observed between the CR and non-CR group (p = 0.915). A residual tumor volume below 20% of the pretreatment volume should be expected at long-term follow-up beyond one year after radiotherapy.

摘要

我们系统地分析了肿瘤消退的动力学、残留病变对疾病控制的影响以及卢加诺分类在光子放射治疗眼眶非霍奇金淋巴瘤随访 MRI 中的适用性。我们回顾性分析了 36 例低级别、Ann-Arbor 分期 I 期眼眶非霍奇金淋巴瘤患者的总共 154 个放疗前后 MRI 数据集。排除了仅限于结膜受累的患者。在 T1 加权序列上对淋巴瘤病变进行描绘和体积分析。在治疗后 6 个月内,所有病例中均有 91.2%存在肿瘤残留。在治疗结束后 12-24 个月、36-48 个月和 >48 个月时,体积部分缓解率(>50%体积减少)分别为 75%、69.2%和 50%。根据卢加诺分类,相应的完全缓解(CR)率分别为 20%、23.1%和 50%。在中位临床随访 37 个月期间,CR 组和非 CR 组的无进展生存(PFS)率无显著差异(p=0.915)。在放疗后一年以上的长期随访中,预计残留肿瘤体积应低于治疗前体积的 20%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cadb/10036339/3254e0507c01/41598_2023_31941_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验